Fournier gangrene
disease diseaseOn this page
Also known as Fournier diseaseFournier's diseaseFournier's gangreneFourniers diseaseFourniers gangrenegangrene, Fourniergangrene, Fournier's
Summary
Fournier gangrene (MONDO:0043352) is a disease and 13 clinical trials. Top therapeutic interventions include sodium chloride, daptomycin, and reltecimod. A subtype of male reproductive system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 13
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | fournier gangrene |
| Mondo ID | MONDO:0043352 |
| MeSH | D018934 |
| ICD-10-CM | N49.3 |
| SNOMED CT | 398318005 |
| UMLS | C0238419 |
| MedGen | 65967 |
| Is cancer (heuristic) | no |
Also known as: Fournier disease · fournier gangrene · Fournier’s disease · Fournier’s gangrene · fournier’s gangrene · Fourniers disease · Fourniers gangrene · gangrene, Fournier · gangrene, Fournier’s
Disease family
This is a subtype of male reproductive system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › fournier gangrene
Related subtypes (25): benign male reproductive system neoplasm, hematocele of tunica vaginalis testis, male genital organ stricture, male genital organ vascular disease, penile disorder, testicular disorder, prostate disorder, epididymitis, hydrocele, male infertility, male genital tuberculosis, spermatocele, dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome, cryptorchidism, diphallia, postorgasmic illness syndrome, penoscrotal transposition, congenital bilateral absence of vas deferens, posterior hypospadias, isolated micropenis, male reproductive system neoplasm, congenital agenesis of the scrotum, scrotal disorder, congenital megaprepuce, epididymis disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 13.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 11 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02469857 | PHASE3 | COMPLETED | Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections |
| NCT02111161 | PHASE2 | COMPLETED | Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial |
| NCT07107555 | Not specified | ENROLLING_BY_INVITATION | Necrotizing Soft Tissue Infections |
| NCT07359651 | Not specified | RECRUITING | FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI). |
| NCT00261807 | Not specified | COMPLETED | Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections |
| NCT02180906 | Not specified | COMPLETED | Biomarkers in Patients With Flesh-eating Bacterial Infections |
| NCT02501382 | Not specified | COMPLETED | Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment |
| NCT03147352 | Not specified | COMPLETED | Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study |
| NCT03443544 | Not specified | COMPLETED | Fournier’s Gangrene and the Origin of the Infection as a Prognostic of Morbidity and Mortality, an Analysis of 121 Patients |
| NCT04694053 | Not specified | COMPLETED | Fournier’s Gangrene in Patient With Uncontrolled Type 2 Diabetes |
| NCT04983056 | Not specified | COMPLETED | Management of Fournier Gangrene at Ibn Rochd University Hospital Center |
| NCT05116956 | Not specified | UNKNOWN | SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study |
| NCT05529628 | Not specified | COMPLETED | The Immunological Differences Between Fournier Gangrene and Perianal Abscess |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SODIUM CHLORIDE | 4 | 2 |
| DAPTOMYCIN | 4 | 1 |
| RELTECIMOD | 3 | 1 |
| CHEMBL1649722 | 0 | 1 |
| CHEMBL4286784 | 0 | 1 |
| CHEMBL4744444 | 0 | 1 |
Related Atlas pages
- Drugs: Sodium Chloride, Daptomycin, Reltecimod